Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EQRx, Inc.CMLT · Entity 108311 | Director | April 06, 2021 | April 06, 2021 |
| Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530 | Director | September 15, 2026 | September 16, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | EVP & Chief Commercial Officer | January 30, 2017 | February 01, 2017 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | See Remarks | March 03, 2026 | March 04, 2026 |
| Wave Life Sciences, Inc.WVE · Entity 4976 | Director | October 05, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EQRx, Inc.
Report date April 06, 2021 · Filed April 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-04-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-253475) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-253475) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Ginkgo Bioworks Holdings, Inc.
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 19,310 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 5,000 · Balance 19,310 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.074 to $7.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.074 to $7.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
ILLUMINA, INC.
Report date January 30, 2017 · Filed February 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,531 |
Reported balance
After 2017-01-30 transaction · row 1
1 source rowRow 1 · 2017-01-30 · Tax withholding · Disposed 795 · Balance 17,531 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date March 03, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,581,813 |
Reported balance
After 2026-03-03 transaction · row 1
1 source rowRow 1 · 2026-03-03 · Sale · Disposed 12,497 · Balance 3,581,813 F1: Represents the number of shares mandatorily sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This sale price represents the weighted average sale price of the shares sold ranging from $1.49 to $1.56 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares mandatorily sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This sale price represents the weighted average sale price of the shares sold ranging from $1.49 to $1.56 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Wave Life Sciences, Inc.
Report date October 05, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,400 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 10,700 · Balance 23,400 F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2036-10-05 | Direct | 64,000 |
Reported balance
After 2026-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-05 · Grant · Acquired 64,000 · Balance 64,000 F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2023 Filed Sep 12, 2023 20:42 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 10,000 | $10.45 | $104,520.00 |
DisclosureSEC source: 0001299130-23-000113 · wf-form4_169455131313168.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,202,939 F1 · shares: The sale was made pursuant to a 10b5-1 plan, as adopted on May 18, 2023. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $10.33 to $10.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:05 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 4,499 | $2.23 | $10,032.77 |
DisclosureSEC source: 0001127602-23-023814 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,243,377 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 20:44 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 10,000 | $10.50 | $105,000.00 |
DisclosureSEC source: 0001299130-23-000111 · wf-form4_169239144206224.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,212,939 F1 · shares: The sale was made pursuant to a 10b5-1 plan, as adopted on May 18, 2023. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $10.39 to $10.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 07, 2023 Filed Aug 10, 2023 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000899243-23-017911 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires 2028-08-07 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2024 annual general meeting or August 7, 2024. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 21:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 4,499 | $2.25 | $10,122.75 |
DisclosureSEC source: 0001127602-23-022032 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,247,876 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 21:04 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 4,499 | $1.89 | $8,503.11 |
DisclosureSEC source: 0001127602-23-020425 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,252,375 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:06 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantStock Option · Derivative | 139,860 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001127602-23-019170 · form4.xml · derivative · entry 2 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,860 Underlying: Class A Common Stock · 139,860 shares Expires 2033-06-16 F3 · shares: In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000. F2 · derivative.exercise_date: The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date. RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023. F3 · derivative.underlying_shares: In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:06 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 105,263 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019170 · form4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,263 Underlying: Class A Common Stock · 105,263 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date. RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023. F2 · derivative.expiration_date: The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date. RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:09 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 39,007 | $1.84 | $71,772.88 |
DisclosureSEC source: 0001127602-23-018722 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,256,874 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:02 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 4,499 | $1.63 | $7,333.37 |
DisclosureSEC source: 0001127602-23-018067 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,295,881 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:20 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 4,499 | $1.16 | $5,218.84 |
DisclosureSEC source: 0001127602-23-014603 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,300,380 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. F1 · shares: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 22:41 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 4,499 | $1.32 | $5,938.68 |
DisclosureSEC source: 0001127602-23-012627 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,304,879 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. F1 · shares: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 21:37 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 4,499 | $1.37 | $6,163.63 |
DisclosureSEC source: 0001127602-23-010472 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,309,378 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. F1 · shares: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:53 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 13,769 | $9.49 | $130,709.12 |
DisclosureSEC source: 0001299130-23-000042 · certent-form4.xml · nonDerivative · entry 2 HENRY CHRISTIAN O · CIK 0001263805 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222,939 F2 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $9.24 to $9.71 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:53 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 594,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-23-000042 · certent-form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,236,708 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15th of each of 2024, 2025, 2026, and 2027, provided that the Reporting Person continues to serve through each applicable vesting date. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 12:34 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 1,530 | $10.27 | $15,714.63 |
DisclosureSEC source: 0001299130-23-000024 · certent-form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642,021 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $9.80 to $10.82 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 4,499 | $2.10 | $9,447.90 |
DisclosureSEC source: 0001127602-23-003394 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,313,877 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. F1 · shares: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 23:21 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 4,499 | $1.57 | $7,063.43 |
DisclosureSEC source: 0001127602-23-001102 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318,376 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. F1 · shares: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 02:10 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 4,499 | $1.85 | $8,323.15 |
DisclosureSEC source: 0000899243-22-037726 · doc4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,322,875 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. F1 · shares: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:47 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 45,000 | $10.84 | $487,980.00 |
DisclosureSEC source: 0001299130-22-000139 · certent-form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,551 F1 · price: This sale price represents the weighted average sale price of the shares sold ranging from $10.76 to $10.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| November 03, 2022 Filed Nov 8, 2022 02:33 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 49,490 | $2.56 | $126,694.40 |
DisclosureSEC source: 0000899243-22-035325 · doc4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,327,374 F1 · kind: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. F1 · shares: Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 23:17 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 91,307 | $5.78 | $527,434.89 |
DisclosureSEC source: 0001299130-22-000112 · certent-form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688,551 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $5.67 to $5.93 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 15, 2022 Filed Aug 18, 2022 00:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000899243-22-029099 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2027-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2023 annual general meeting or August 15, 2023. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 01:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantStock Option · Derivative | 108,516 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0000899243-22-022289 · doc4.xml · derivative · entry 2 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,516 Underlying: Class A Common Stock · 108,516 shares Expires 2032-06-10 F2 · shares: In accordance with the Non-Employee Director Compensation Policy of the Issuer, the Black-Scholes value of the option award as of the grant date is $200,000. F1 · derivative.exercise_date: The vesting date of the restricted stock units and stock options, and in the case of the stock options, the exercise date, will be the earlier of either June 10, 2023 or the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 01:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantClass A Common Stock | 70,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-022289 · doc4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,376,864 F1 · shares: The vesting date of the restricted stock units and stock options, and in the case of the stock options, the exercise date, will be the earlier of either June 10, 2023 or the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 01:34 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantClass A Common Stock | 1,071,395 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010988 · doc4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,305,943 F1 · kind: The reporting person was previously granted awards of restricted stock units covering Class A Common Stock, which vest based upon the Issuer's achievement of an event condition (i.e., an underwritten initial public offering or a change in control), subject to additional time based vesting conditions in accordance with the terms of the award. On March 11, 2022, the Compensation Committee of the Issuer's Board of Directors, after consideration of the completion of the initial business combination, modified the event condition, resulting in the immediate vesting of 883,253 restricted stock units for which the time based vesting requirements had been satisfied as of December 31, 2021 and the issuance of a corresponding number of shares of Class A Common Stock. The remaining restricted stock units will continue to vest in accordance with the terms of the award. F1 · shares: The reporting person was previously granted awards of restricted stock units covering Class A Common Stock, which vest based upon the Issuer's achievement of an event condition (i.e., an underwritten initial public offering or a change in control), subject to additional time based vesting conditions in accordance with the terms of the award. On March 11, 2022, the Compensation Committee of the Issuer's Board of Directors, after consideration of the completion of the initial business combination, modified the event condition, resulting in the immediate vesting of 883,253 restricted stock units for which the time based vesting requirements had been satisfied as of December 31, 2021 and the issuance of a corresponding number of shares of Class A Common Stock. The remaining restricted stock units will continue to vest in accordance with the terms of the award. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 00:21 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 642,300 | $0.00 Strike: $11.70 | $0.00 |
DisclosureSEC source: 0001299130-22-000033 · certent-form4.xml · derivative · entry 2 HENRY CHRISTIAN O · CIK 0001263805 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642,300 Underlying: Common Stock · 642,300 shares Expires 2032-03-02 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the next four years, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 00:21 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 107,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-22-000033 · certent-form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779,858 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on March 2 of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommons Stock | 2,122 | $11.09 | $23,532.98 |
DisclosureSEC source: 0001299130-22-000024 · certent-form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,358 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $11.08 to $11.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| September 16, 2021 Filed Sep 17, 2021 20:53 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 90,520 | $26.91 | $2,435,893.20 |
DisclosureSEC source: 0001299130-21-000198 · certent-form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674,480 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 16, 2021 Filed Sep 21, 2021 01:40 UTC Amendment | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 90,520 | $26.91 | $2,435,893.20 |
DisclosureSEC source: 0001299130-21-000204 · certent-form4a.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674,480 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $26.72 to $27.08 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4/A. Read SEC document |
| September 16, 2021 Filed Sep 21, 2021 01:44 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantClass A Common Stock | 234,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036675 · doc4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,548 F1 · shares: Reflects earn-out shares that will vest in four substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $12.50, $15.00, $17.50 and $20.00. F2 · price: Pursuant to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. ("Legacy Ginkgo"), as contemplated by an agreement and plan of merger, dated May 11, 2021 as amended on May 14, 2021 (the "Merger Agreement"), each share of Class A common stock of Legacy Ginkgo, each share of Class B common stock of Legacy Ginkgo, each option of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, each award of restricted common stock of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, and each award of restricted stock units of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, in each case outstanding immediately prior to the effective time of the business combination, received a proportional amount of the approximately 188.7 million earn-out shares. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:08 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0000899243-21-033520 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Ordinary Shares · 42,000 shares Expires 2026-08-16 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 12.5% of the shares in equal quarterly installments over the two-year period following the grant date on August 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:42 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $46.37 | $0.00 |
DisclosureSEC source: 0001299130-21-000066 · certent-form4.xml · derivative · entry 2 HENRY CHRISTIAN O · CIK 0001263805 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-02-16 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the next four years, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:42 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-21-000066 · certent-form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,000 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 16 of each of 2022, 2023, 2024, and 2025, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 1,500,000 | $0.00 Strike: $7.32 | $0.00 |
DisclosureSEC source: 0001209191-20-050870 · doc4.xml · derivative · entry 2 HENRY CHRISTIAN O · CIK 0001263805 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2030-09-15 F2 · derivative.exercise_date: 1/4 of the shares subject to the option will vest on the one year anniversary of the date of grant, and the balance of shares will vest monthly thereafter over the next three years, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050870 · doc4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on September 15 of each of 2021, 2022, 2023, and 2024, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:28 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023078 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 22:43 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 97,785 | $0.00 Strike: $3.89 | $0.00 |
DisclosureSEC source: 0001209191-20-045569 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,785 Underlying: Common Stock · 97,785 shares Expires 2030-08-04 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, or if earlier, on the date of the Issuer's next annual meeting of stockholders, provided that the Reporting Person continues to serve as a director through each vesting date. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:08 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001209191-20-019320 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: 1/3 of the shares subject to the option will vest on the one year anniversary of the date of grant, and the balance of shares will vest monthly thereafter over the next two years, provided that the Reporting Person continues to serve as a director through each vesting date. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:21 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0000899243-19-021966 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2024-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020. Read SEC document |
| August 13, 2018 Filed Aug 16, 2018 00:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $46.70 | $0.00 |
DisclosureSEC source: 0000899243-18-022514 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2023-08-13 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019. Read SEC document |
| July 27, 2018 Filed Jul 31, 2018 20:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001209191-18-044539 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-07-27 F1 · derivative.exercise_date: 1/3 of the shares subject to the option will vest on the one year anniversary of the date of grant, and the balance of shares will vest monthly thereafter over the next two years, provided that the Reporting Person continues to serve as a director through each vesting date. Read SEC document |
| August 10, 2017 Filed Aug 17, 2017 20:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $18.10 | $0.00 |
DisclosureSEC source: 0000899243-17-020600 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2022-08-10 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 10, 2018. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 00:29 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 795 | $159.28 | $126,627.60 |
DisclosureSEC source: 0001127602-17-003220 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,531 Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 22:53 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0000899243-16-033365 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Ordinary Shares · 18,000 shares Expires 2021-11-10 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 25% of the shares on November 10, 2017 and vests as to an additional 2.0833% of the shares monthly thereafter until November 10, 2020. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 01:31 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 650 | $137.08 | $89,102.00 |
DisclosureSEC source: 0001127602-16-066463 · form4.xml · nonDerivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,326 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.